#### East Tennessee State University

#### Digital Commons @ East Tennessee State University

Appalachian Student Research Forum

2019 ASRF Schedule

Apr 12th, 2:00 PM - 2:15 PM

# Synthesis and Evaluation of 1,2,4-oxadiazolidinones: The Search for Potential non- $\beta$ -lactam $\beta$ -lactamase Inhibitors.

Chimdi E. Kalu East Tennessee State University

Noah Lyons East Tennessee State University

Abbas G. Shilabin East Tennessee State University

Chimdi Kalu East Tennessee State University

Follow this and additional works at: https://dc.etsu.edu/asrf

Kalu, Chimdi E.; Lyons, Noah; Shilabin, Abbas G.; and Kalu, Chimdi, "Synthesis and Evaluation of 1,2,4-oxadiazolidinones: The Search for Potential non- $\beta$ -lactam  $\beta$ -lactamase Inhibitors." (2019). *Appalachian Student Research Forum*. 159. https://dc.etsu.edu/asrf/2019/schedule/159

This Oral Presentation is brought to you for free and open access by the Events at Digital Commons @ East Tennessee State University. It has been accepted for inclusion in Appalachian Student Research Forum by an authorized administrator of Digital Commons @ East Tennessee State University. For more information, please contact digilib@etsu.edu.

# Synthesis of 1,2,4-oxadiazolidinone derivatives: The Search for Potential Non-β-lactam β-Lactamases Inhibitors

presented by

#### Chimdi Kalu

Supervisor: Dr. Abbas G. Shilabin

## Outline

- Introduction
- Research objectives
- Bacteria cell wall structure
- β-lactam antibiotic drugs
- Non  $\beta$ -lactam  $\beta$ -lactamase inhibitor
- Synthesis, characterization, and biological activites of 1,2,4-oxadiazolidinone analogs
- Conclusion

## **Research Objectives**

- To synthesize a 1,2,4-oxadiazolidinone derivatives via 1,3dipolar cycloaddition of nitrones with substituted isocyanates.
- To evaluate the biological significance of the synthesized inhibitors.
- To improve or restore the potency of antibiotic agents that lost their effectiveness due to continuous evolution of bacteria's  $\beta$ -lactamases.

#### **Bacterial cell wall**




Figure 1: A section of Gram-negative and Gram-positive cell wall

### β-lactam antibiotic drugs




Figure 2: Some β-lactam Antibiotics

#### **Bacteria**' β-lactamases




Figure 3: Mechanism of resistance to antibiotics.

#### Justification of 1,2,4-oxadiazolidin-5-one





Figure 4: Comparison of compound of interest with Avibactam and linezolid

https://pubchem.ncbi.nlm.nih.gov/compound/9835049 www.idstewardship.com/drugs/ceftazidime-avibactam http://www.avalonpharmacy.com/product/zyvox-linezolid/


#### **Synthesis of nitrones**



#### Scheme 1: Reaction of nitro compounds with benzaldehyde.

Ritter, T., Carreira, E. M. Angew. Chem., Int. Ed. 2005, 44 (6), 936-938

### 1,3-dipolar cycloaddition reaction



Scheme 2: Reaction of nitrones with various isocyanates

DOI: 10.1002/anie.200461934

#### CHARACTERIZATION AND BIOLOGICAL ACTIVITIES







Figure 5: <sup>1</sup>H & <sup>13</sup>C NMR spectra of Nitrone 1a







Figure 6: <sup>1</sup>H & <sup>13</sup>C NMR spectra of oxadiazolidinone 2a




S

Figure 7: <sup>1</sup>H & <sup>13</sup>C NMR spectra of compound 2c

# of Peaks436Raw Spectrum11.139BackgroundNo BacExact mass280

11.139 (scan: 878) No Background Spectrum 280






Figure 8: GC-MS spectrum of compound 2c




Figure 9: IR spectra of compound 2c

### **Demonstration of cycloaddition**






Figure 10: <sup>1</sup>H NMR spectra of 1a and corresponding oxadiazolidinone 2a

# **Table 1**: The cytotoxicity essay (%) of **2a** on relative control (100%) against IGROV1, OVCAR-4, HS 578T, BT-549, A498, UO-31, UACC-62, SK-MEL-28

Cancer types	Cell line	Growth %	% Inhibition	
Ovarian Cancer	IGROV1	95.59	4.41	
	OVCAR-4	95.84	4.16	
Breast Cancer	HS 578T	93.06	6.94	
	BT-549	99.50	0.50	
Renal Cancer	A498	82.27	17.73	
	UO-31	86.72	13.33	
Melanoma	UACC-62	93.93	6.07	
	SK-MEL-28	99.89	0.11	



#### **Enzyme Inhibition Kinetics**



# **Table 2**: Residual Activity and Percent Inhibition of TEM-1 for 3 minutes, 30°C Utilizing Potential Synthesized Inhibitors<sup>\*</sup>

Compound	Molecular Weight (g/mol)	Initial Rate V <sub>°</sub> ± SD (ΔA, sec <sup>-1</sup> ) × 10 <sup>-3</sup>	Initial Rate +Inhibitor $V_i \pm SD (\Delta A, sec^{-1}) \times 10^{-3}$	Residual Activity (%)	% Inhibition
2a	268.31	$1.6870 \pm 0.01531$	$\begin{array}{c} 1.2930 \pm \\ 0.03163 \end{array}$	76.47	23.53
2b	254.28	$2.9367 \pm 0.26697$	$2.1840 \pm 0.34975$	74.37	25.63
2C	280.00	1.159 ± 0.01139	1.0139 ± 0.02758	87.48	12.52
3	252.29	$2.0411 \pm 0.01252$	$\begin{array}{c} 1.2465 \pm \\ 0.01698 \end{array}$	61.07	38.93
3 (P99)	252.29	$7.1434 \pm 0.15520$	$5.5067 \pm 0.15981$	77.09	22.91

## Conclusion

- In this work, oxadiazolidinone derivatives (2a, 2b, 2c, and 3), were prepared using commercially available isocyanate derivatives with synthesized nitrone 1a and 1b. The synthesized inhibitors were characterized using <sup>1</sup>H and <sup>13</sup>C NMR, GC-MS, and IR.
- Afterwards, there were tested against TEM-1 and P99 serine β-lactamase. Compound **2a**, **2b**, **2c**, and **3** showed inhibition ranging from 12-38% and **3** showed 22% inhibition against P99
- MTT Essay was used to test the in vitro cytotoxicity of oxadiazolidinone **2a** on cancer cell lines. **2a** had more activity on renal cancer, decreasing the cell viability of 786-0 by about 18%. The activity on other cell lines ranged from 4-14%.

## Acknowledgement

- God almighty,
- My parents,
- Dr. Abbas G. Shilabin,
- David Mingle, Noah Lyon, Austin Miller, Joseph Osazee.
- Department of Chemistry and the School of Graduate Studies at ETSU.

